Scientific Literature Search

Source record

Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.

Kobylecki C, Burn DJ, Kass-Iliyya L, Kellett MW, Crossman AR, Silverdale MA.

Parkinsonism Relat Disord · 2014-01-28

DOI: 10.1016/j.parkreldis.2014.01.016PMID: 24521874

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Source record

Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.

Morin N, Jourdain VA, Morissette M, Grégoire L, Di Paolo T.

Neuropharmacology · 2014-01-20

DOI: 10.1016/j.neuropharm.2014.01.014PMID: 24456747

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Source record

Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.

Dézsi L, Vécsei L.

Expert Opin Drug Metab Toxicol · 2014-01-17

DOI: 10.1517/17425255.2014.878702PMID: 24437461

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Source record

Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.

Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, Mata M, Olmedilla Gonzalez N, Mahillo Fernandez I.

J Neurol Neurosurg Psychiatry · 2014-01-16

DOI: 10.1136/jnnp-2013-306787PMID: 24434037

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Source record

Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease.

Tereshchenko J, Maddalena A, Bähr M, Kügler S.

Neurobiol Dis · 2014-01-15

DOI: 10.1016/j.nbd.2014.01.009PMID: 24440408

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Open access

N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities.

Bavarsad Shahripour R, Harrigan MR, Alexandrov AV.

Brain Behav · 2014-01-13

DOI: 10.1002/brb3.208PMID: 24683506

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Source record

Hypomania and mania related to dopamine replacement therapy in Parkinson's disease.

Maier F, Merkl J, Ellereit AL, Lewis CJ, Eggers C, Pedrosa DJ, Kalbe E, Kuhn J, Meyer TD, Zurowski M, Timmermann L.

Parkinsonism Relat Disord · 2014-01-12

DOI: 10.1016/j.parkreldis.2014.01.001PMID: 24467817

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Source record

Gene therapy for Parkinson's disease: a step closer?

Stoessl AJ.

Lancet · 2014-01-10

DOI: 10.1016/s0140-6736(13)62108-xPMID: 24412047

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Source record

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA.

Lancet · 2014-01-10

DOI: 10.1016/s0140-6736(13)61939-xPMID: 24412048

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Source record

Initiating levodopa therapy for Parkinson's disease.

Olanow CW, Kieburtz K, Stocchi F.

Mov Disord · 2014-01-09

DOI: 10.1002/mds.25805PMID: 24408661

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Source record

Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.

Sensi M, Preda F, Trevisani L, Contini E, Gragnaniello D, Capone JG, Sette E, Golfre-Andreasi N, Tugnoli V, Tola MR, Quatrale R.

J Neural Transm (Vienna) · 2014-01-08

DOI: 10.1007/s00702-013-1153-3PMID: 24398781

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Source record

Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins.

Guerrero-Muñoz MJ, Castillo-Carranza DL, Kayed R.

Biochem Pharmacol · 2014-01-07

DOI: 10.1016/j.bcp.2013.12.023PMID: 24406245

A bibliographic record traceable to Europe PMC.

Article details View source ↗

Records come from scientific sources. Bibliographic counts do not represent completed translations or editorial approvals.

10.361 articles found

Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.

Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.

Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.

Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.

Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease.

N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities.

Hypomania and mania related to dopamine replacement therapy in Parkinson's disease.

Gene therapy for Parkinson's disease: a step closer?

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Initiating levodopa therapy for Parkinson's disease.

Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.

Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins.

Filters